Andrew Parece and Urs Wiedemann published an article in the April issue of Pharmaceutical Executive. The authors discuss outcomes-based, risk-sharing agreements as one approach to change the dialogue between manufacturers and payers, from price to value. To read the article, click the link below.
Navigating payer challenges in rare disease
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...